var _paq = window._paq = window._paq || []; /* tracker methods like "setCustomDimension" should be called before "trackPageView" */ _paq.push(['trackPageView']); _paq.push(['enableLinkTracking']); (function() { var u="https://rwrregs.matomo.cloud/"; _paq.push(['setTrackerUrl', u+'matomo.php']); _paq.push(['setSiteId', '1']); var d=document, g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true; g.data-privacy-src='//cdn.matomo.cloud/rwrregs.matomo.cloud/matomo.js'; s.parentNode.insertBefore(g,s); })();

Real World Evidence (RWE) 101 – Pregnancy Registries

RWE 101 – Pregnancy Registries

A pregnancy registry is a type of real-world evidence collection system that collects data from pregnant women who have been exposed to a particular medication, vaccine, or medical intervention during pregnancy. The purpose of a pregnancy registry is to gather information about the safety and effectiveness of these exposures in pregnant women and their offspring.

Pregnancy registries are important because pregnant women are often excluded from clinical trials due to safety concerns, which can limit the amount of data available about the safety and effectiveness of medications, vaccines, and medical inyterventions during pregnancy. By collecting data from pregnant women who have been exposed to these agents, pregnancy registries can provide valuable information to healthcare providers and patients to help guide treatment decisions during pregnancy.

A pregnancy registry typically collects information about the mother’s health status, the medication or medical intervention being studied, and pregnancy outcomes such as miscarriage, stillbirth, preterm birth, and birth defects. The data collected can be used to identify potential safety signals or adverse effects associated with the medication or medical intervention, and to evaluate the overall safety and effectiveness of the treatment in pregnant women.

In summary, pregnancy registries are an important tool in real-world evidence collection for understanding the safety and effectiveness of medications, vaccines, and medical interventions during pregnancy. By gathering data from pregnant women who have been exposed to these agents, pregnancy registries can provide valuable information to healthcare providers and patients to help guide treatment decisions and improve the health outcomes of both mother and child.

Share this story...

Real World Evidence (RWE) 101 – Pregnancy Registries2023-08-07T23:03:15+00:00

Real World Evidence (RWE) 101 – Diversity

RWE 101 – Diversity

Diversity in the context of real-world research refers to the inclusion of individuals from different backgrounds, including but not limited to race, ethnicity, gender, age, sexual orientation, socioeconomic status, and geographic location. It is important to ensure diversity in research because it can provide a more comprehensive understanding of health and healthcare outcomes, as well as enable the development of interventions that are effective for all populations.

In the past, research has often focused on populations that are easier to access, which has led to underrepresentation of certain groups in research studies. This lack of diversity can result in biased and incomplete research findings that do not accurately reflect the experiences and health outcomes of all populations.

Therefore, it is crucial for real-world research to include diverse populations to ensure that research findings can be generalized to all groups. This can help to identify health disparities, understand the root causes of these disparities, and develop interventions that are effective for all populations.

In summary, diversity in real-world research means including individuals from diverse backgrounds to ensure that research findings are inclusive, representative, and generalizable to all populations. By doing so, research can more effectively identify and address health disparities and improve health outcomes for all individuals.

Share this story...

Real World Evidence (RWE) 101 – Diversity2023-08-07T23:02:07+00:00

Real World Evidence (RWE) 101 – The Patient Voice

RWE 101 – The Patient Voice

The patient voice refers to the perspectives, opinions, and experiences of patients and their families or caregivers in the context of healthcare research. It is a term used to describe the active involvement of patients in the design, execution, and dissemination of research studies that aim to improve health outcomes and patient care.

In the past, patients were often viewed as passive recipients of healthcare services and were not considered to have an active role in research. However, in recent years, there has been a growing recognition of the importance of including the patient voice in healthcare research. This recognition is driven by the belief that patients have unique insights and perspectives that can help researchers better understand their experiences, preferences, and priorities.

The patient voice is particularly important in real-world research, which focuses on understanding healthcare outcomes in the context of everyday clinical practice. By including patients in the research process, researchers can ensure that the research questions and outcomes are relevant and meaningful to patients. This can lead to more patient-centered research that has the potential to improve patient outcomes and quality of life.

Overall, the patient voice is an essential component of real-world research, as it helps to ensure that research is conducted in a way that is responsive to the needs and priorities of patients.

Share this story...

Real World Evidence (RWE) 101 – The Patient Voice2023-08-07T23:00:50+00:00

Real World Evidence (RWE) 101 – ISPE GPP

RWE 101 – ISPE GPP

The International Society of Pharmacoepidemiology (ISPE) Good Pharmacoepidemiology Practices (GPP) provides guidance for the conduct and reporting of pharmacoepidemiologic studies. The key points of ISPE GPP include:

Study Design and Conduct: ISPE GPP emphasizes the importance of study design and conduct to ensure the validity and reliability of study results. The guide provides guidance on study design, sample selection, data collection, and analysis.

Data Sources and Quality: ISPE GPP provides guidance on the selection and use of data sources, such as administrative databases, electronic health records, and patient registries. The guide emphasizes the importance of data quality and the need to validate data sources and ensure data completeness.

Ethical Considerations: ISPE GPP emphasizes the importance of ethical considerations in pharmacoepidemiologic studies, including informed consent, confidentiality, and protection of human subjects.

Reporting and Dissemination of Results: ISPE GPP provides guidance on the reporting and dissemination of study results, including the need to provide clear and transparent reporting of study methods, results, and limitations.

Collaboration and Communication: ISPE GPP emphasizes the importance of collaboration and communication among researchers, stakeholders, and the public to ensure the appropriate use and interpretation of study results.

Share this story...

Real World Evidence (RWE) 101 – ISPE GPP2023-08-07T22:59:38+00:00

Real World Evidence (RWE) 101 – EMA Good Pharmacovigilance Practices (GVPs)

RWE 101 – EMA Good Pharmacovigilance Practices (GVPs)

The European Medicines Agency’s (EMA) Good Pharmacovigilance Practices (GVPs) provide a framework for the monitoring and reporting of adverse drug reactions (ADRs) to ensure the safety and efficacy of medicines. In the context of real-world evidence, GVPs play an important role in ensuring the quality and reliability of data collected from real-world studies.

Real-world evidence refers to data collected from sources outside of traditional clinical trials, such as electronic health records, patient registries, and observational studies. This type of data is becoming increasingly important in drug development and regulatory decision-making, as it provides valuable insights into how medicines perform in real-world settings.

To ensure the quality and reliability of real-world evidence, GVPs require that data collection methods are standardized and that the data is collected in a manner that minimizes bias and confounding factors. GVPs also require that adverse events are reported in a timely and accurate manner, and that data is regularly monitored for safety signals.

In addition, GVPs require that all stakeholders involved in the collection and use of real-world evidence are trained (as appropriate) in pharmacovigilance principles and are aware of their responsibilities in ensuring the safety and efficacy of medicines.

By adhering to GVPs in the context of real-world evidence, researchers and regulatory agencies can ensure that the data collected is of high quality and can be used to inform decision-making related to the safety and efficacy of (approved) medicines.

Share this story...

Real World Evidence (RWE) 101 – EMA Good Pharmacovigilance Practices (GVPs)2023-08-07T22:58:35+00:00

Real World Evidence (RWE) 101 – Is ICH GCP Applicable to Non-Interventional Studies?

RWE 101 – Is ICH GCP Applicable to Non-Interventional Studies?

No, the International Council for Harmonisation (ICH) Good Clinical Practice (GCP) guidelines are not applicable to non-interventional studies (NIS) in the context of real-world evidence (RWE).

ICH GCP guidelines are designed to ensure the protection of human subjects and the quality and integrity of data generated in clinical trials of investigational medicinal products (IMPs). In contrast, NIS are observational studies that do not involve the administration of IMPs, and instead rely on the collection of data from routine clinical practice or other non-experimental settings.

However, there are other guidelines and frameworks that apply to non-interventional studies in the context of real-world evidence, such as the International Society for Pharmacoepidemiology’s (ISPE) “Guidelines for Good Pharmacoepidemiology Practices” (GPP).

It is important to note that while NIS may not be subject to the same regulatory requirements as clinical trials, they still need to adhere to the applicable local regulations, ethical and scientific standards, and to ensure the protection of patient privacy and confidentiality.

Share this story...

Real World Evidence (RWE) 101 – Is ICH GCP Applicable to Non-Interventional Studies?2023-08-07T22:57:28+00:00

Real World Evidence (RWE) 101 – Ethical Principles and Safeguards for Medical AI in the Context of Real World Evidence

RWE 101 – Real World Evidence (RWE) 101 – Ethical Principles and Safeguards for Medical AI in the Context of Real World Evidence

Medical AI applications hold great promise for improving healthcare outcomes, but they also raise ethical concerns related to patient privacy, algorithmic bias, and the reliability of the underlying data. When deploying medical AI in the context of real-world evidence, there are several ethical principles and safeguards that should be considered:

Transparency: Medical AI algorithms should be transparent about how they make decisions, what data they use, and the potential limitations of their predictions. This allows patients and clinicians to better understand the reasoning behind the AI’s recommendations and assess its accuracy.

Data privacy: Medical AI algorithms should comply with data privacy regulations, such as HIPAA in the United States, and should ensure that patient data is protected from unauthorized access, use, or disclosure.

Informed consent: Patients should be informed about how their data will be used by medical AI algorithms and should provide explicit consent for its use. They should also have the right to withdraw their consent at any time.

Fairness and bias: Medical AI algorithms should be designed to minimize bias and ensure that their predictions are fair across different patient populations. This requires careful attention to the selection of training data and the use of appropriate validation methods.

Human oversight: Medical AI algorithms should be designed to augment, not replace, human decision-making. Clinicians should have the ability to review and modify the AI’s recommendations, and patients should have access to human experts to address any concerns or questions they may have.

Accountability: Developers and providers of medical AI applications should be accountable for the accuracy and reliability of their algorithms, and should be transparent about any limitations or uncertainties associated with their predictions.

By following these ethical principles and safeguards, medical AI can be deployed in a responsible and effective manner, enabling healthcare providers to make better-informed decisions and improve patient outcomes.

Share this story...

Real World Evidence (RWE) 101 – Ethical Principles and Safeguards for Medical AI in the Context of Real World Evidence2023-08-07T22:56:13+00:00

Real World Evidence (RWE) 101 – The Declaration of Helsinki

RWE 101 – The Declaration of Helsinki

The Declaration of Helsinki is a set of ethical principles that govern the conduct of medical research involving human subjects. It was first adopted in 1964 and has been revised several times since then, most recently in 2013.

In the context of real-world evidence (RWE), the Declaration of Helsinki is particularly relevant because RWE often involves the collection and analysis of data from sources that were not originally intended for research purposes, such as electronic health records or claims data. This raises important ethical considerations, such as privacy and confidentiality concerns, and the need to obtain informed consent from study participants.

The Declaration of Helsinki provides guidance on these and other ethical issues related to medical research involving human subjects. For example, it states that research involving human subjects must be conducted in accordance with ethical principles, including respect for persons, beneficence, and justice. It also emphasizes the importance of obtaining informed consent from study participants, protecting their privacy and confidentiality, ensuring that the risks and benefits of the research are appropriately balanced, and ensuring research transparency by publishing the results (both positive and negative).

In the context of RWE, these ethical principles can help guide the development and implementation of research studies that use real-world data. For example, researchers can use the Declaration of Helsinki as a framework for designing studies that protect the privacy and confidentiality of study participants, obtain informed consent, and balance the risks and benefits of the research.

Overall, the Declaration of Helsinki provides important ethical guidance for medical research involving human subjects, including research that uses real-world data. Adhering to these principles can help ensure that RWE studies are conducted in an ethical and responsible manner.

Share this story...

Real World Evidence (RWE) 101 – The Declaration of Helsinki2023-08-07T22:55:06+00:00

Real World Evidence (RWE) 101 – Ethical Foundation of RWE Research

RWE 101 – Real World Evidence (RWE) 101 – Ethical Foundation of RWE Research

Real-world evidence (RWE) research, which is the study of data from real-world settings, is founded on a number of ethical principles, including:

Respect for autonomy: This principle recognizes the importance of individuals’ ability to make their own decisions regarding their healthcare. In RWE research, this means obtaining informed consent from individuals before using their data.

Beneficence: This principle requires that researchers seek to maximize the benefits of their research while minimizing any potential harm. In RWE research, this means ensuring that the research is designed to answer important questions that will improve health outcomes for individuals.

Non-maleficence: This principle requires that researchers avoid causing harm to study participants. In RWE research, this means minimizing any risks associated with data collection and use, such as breaches of confidentiality.

Justice: This principle requires that researchers treat individuals fairly and equitably, ensuring that the benefits and burdens of the research are distributed fairly. In RWE research, this means ensuring that the use of data is transparent and that individuals are not unfairly excluded from research opportunities.

In addition to these principles, RWE research is also guided by ethical standards established by international bodies, such as the World Medical Association’s Declaration of Helsinki. These standards emphasize the importance of obtaining informed consent, protecting privacy and confidentiality, and ensuring that research is conducted in a manner that respects the dignity and rights of study participants.

Share this story...

Real World Evidence (RWE) 101 – Ethical Foundation of RWE Research2023-08-07T22:52:57+00:00

Real World Evidence (RWE) 101 – The Impact of GDPR on RWE Research

RWE 101 – Real World Evidence (RWE) 101 – The Impact of GDPR on RWE Research

The General Data Protection Regulation (GDPR) is a regulation in EU law on data protection and privacy for all individuals within the European Union (EU) and the European Economic Area (EEA). Its implementation in May 2018 has had a significant impact on research, particularly in the context of real-world evidence (RWE).

RWE refers to data collected outside of the traditional clinical trial setting, such as electronic health records (EHRs), claims data, and patient-generated data. RWE is increasingly being used to support regulatory decisions and to inform clinical practice. However, the use of RWE must comply with GDPR, which has implications for the collection, processing, and use of personal data in research.

Under GDPR, personal data must be collected and processed lawfully, fairly, and transparently, and individuals have the right to be informed about how their data is being used. This means that researchers must obtain explicit and informed consent from individuals to use their personal data for research purposes. In addition, the data must be pseudonymized or anonymized to protect individuals’ privacy.

GDPR has also increased the administrative burden for researchers, who must ensure that their data management practices are compliant with GDPR. This includes developing and implementing policies and procedures for data protection, privacy, and security, as well as appointing a Data Protection Officer to oversee data management activities.

Overall, GDPR has had a positive impact on research by increasing transparency and protecting the privacy of individuals whose data is used in research. However, compliance with GDPR can be challenging, particularly in the context of RWE, where large volumes of data are collected from multiple sources. It is essential for researchers to work closely with data protection and privacy experts to ensure that their research practices are compliant with GDPR.

Share this story...

Real World Evidence (RWE) 101 – The Impact of GDPR on RWE Research2023-08-07T22:51:18+00:00
Help

About Us

Contact Us

Our Values

SSO Login

Follow Us

Newsletter

LinkedIn

[…]

Legal Info

Privacy Policy

Terms and Conditions

Copyright 2026 | Real-World Research Limited | All Rights Reserved |

This website uses cookies and third party services. Settings OK Reject

Cookies

We use analytical tools (Google Analytics) to help us improve the user experience. We DO NOT sell or use any of this data for any purpose beyond improving the design and usability of our own website (rwr-regs.com).
Go to Top